Federated Hermes
ABUS icon

Federated Hermes’s Arbutus Biopharma ABUS Stock Holding History

Federated Hermes’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3
Closed -$12 – 2069
2024
Q3 		$12 Buy
+3
New +$12 ﹤0.01% 2045
2024
Q2 		– Sell
-11,033
Closed -$28.5K – 2020
2024
Q1 		$28.5K Buy
+11,033
New +$28.6K ﹤0.01% 1685
2021
Q4 		– Sell
-619
Closed -$3K – 2197
2021
Q3 		$3K Sell
619
-514
-45% -$1.71K ﹤0.01% 2060
2021
Q2 		$3K Buy
1,133
+137
+14% +$424 ﹤0.01% 2064
2021
Q1 		$3K Buy
+996
New +$3.84K ﹤0.01% 2088
2018
Q4 		– Sell
-563
Closed -$5K – 2184
2018
Q3 		$5K Buy
563
+10
+2% +$99 ﹤0.01% 2048
2018
Q2 		$4K Buy
+553
New +$3.29K ﹤0.01% 2031

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Federated Hermes's ABUS Position: Q4 2024 in Review

Federated Hermes sold out of Arbutus Biopharma (ABUS) in Q4 2024, closing a stake of 3 shares — an estimated $12 sold.

Federated Hermes first reported a position in ABUS in Q2 2018 and held it in 7 quarters. The position peaked at $28.5K in Q1 2024. 153 funds tracked by Wall St. Rank hold ABUS as of Q4 2024.

  • Federated Hermes reported no remaining Arbutus Biopharma position as of Q4 2024 after selling out during the quarter.
  • Federated Hermes sold 3 Arbutus Biopharma shares in Q4 2024, an estimated $12.
  • Federated Hermes first reported a position in Arbutus Biopharma in Q2 2018 and held it in 7 quarters.
  • Federated Hermes's Arbutus Biopharma position peaked at $28.5K in Q1 2024.
  • 153 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2024.

Based on Federated Hermes's 13F filing for Q4 2024, filed 13 Feb 2025.